Clinical trials: mRNA Vaccine
COVID -19, SARS CoV 2 Infection
Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus that emerged in the human population in Wuhan City, Hubei Province, China in December 2019.
- Trial name
- NCT07408297
- Testing
- Janssen Ad26COVS1, Pfizer-BioNTech vaccine COVID-19 vaccine, Inactivated Sinopharm or Sinovac COVID-19 vaccine
- Where
- Kenya
- Volunteers
- 1,919 people, healthy volunteers welcome
- Sponsor
- Victoria Biomedical Research Institute
SARS-CoV-2
A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations
The purpose of this study is to investigate the immunogenicity and safety of mRNA COVID-19 variant-containing vaccine formulations against the vaccine-matched variants and newly emerged variants of severe acute respiratory…
- Trial name
- NCT06585241
- Testing
- mRNA-1273 Variant-containing Formulation
- Where
- 6 sites in United States
- Volunteers
- 1,144 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
COVID-19 Vaccine
SARS-CoV-2 Antibody Response in Children Aged 5-11 Years Following Vaccination Against COVID-19
There are few data on the immunogenicity of the Pfizer-Biontec BNT162b2 vaccine for the prevention of COVID-19 disease and of side effects in children aged 5-11 years.
- Trial name
- NCT05175989
- Where
- Israel
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Rabin Medical Center
COVID-19
A Study of an Investigational Flu Seasonal/SARS-CoV-2 Combination Vaccine in Adults
This study will evaluate the reactogenicity, safety, and immune response of Flu Seasonal/SARS-CoV-2 mRNA (mRNA Flu/COVID-19) combination vaccine.
- Trial name
- NCT06680375
- Testing
- Flu Seasonal /SARS-CoV-2 mRNA Dose 1, Flu Seasonal /SARS-CoV-2 mRNA Dose 2, Flu Seasonal mRNA
- Where
- 9 sites in United States
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
SARS-CoV-2
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of Age
This study will evaluate 2 dose levels of mRNA-1283 in participants ≥6 months to <12 years to determine the optimal dose level per age group.
- Trial name
- NCT07808697
- Testing
- mRNA-1283, mRNA-1273
- Where
- 31 sites in United States, Argentina and 4 more
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
SARS-CoV2 Infection, Immunisation Reaction
Effect of Different SARS-CoV-2 Vaccine Schedules and Vaccination Intervals on Reactogenicity and Humoral Immunogenicity
Investigation of the reactogenicity and immunogenicity of homologous and heterologous vaccine combinations with regard to the formation of SARS-CoV-2 antispike antibodies in health care workers after basic immunization and boost…
- Conditions
- SARS-CoV2 Infection, Immunisation Reaction, Antibody Hypersensitivity, Tolerance
- Trial name
- NCT05076227
- Testing
- IM injection of vaccination (mRNA vaccination), IM injection of vaccination (vector based vaccination)
- Where
- Germany
- Volunteers
- 1,206 people, healthy volunteers welcome
- Sponsor
- Serge Thal
HIV-1-infection
A Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644)
A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) in HIV-1 Uninfected Adults in Good General Health.
- Trial name
- NCT05414786
- Testing
- eOD-GT8 60mer mRNA Vaccine (100µg)
- Where
- 2 sites in Rwanda, South Africa
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- International AIDS Vaccine Initiative
Influenza, Human
A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults
The purpose of this study is to assess the safety and immune response of GlaxoSmithKlines (GSK) messenger RNA (mRNA)-based multivalent vaccine (GSK4382276A) candidate against influenza, administered in healthy younger adults (YA)…
- Trial name
- NCT06431607
- Testing
- F2G22B/DL001Z, F2H23D/DL001Z-NH, F2H23B/DL001Z-NH
- Where
- 18 sites in United States
- Volunteers
- 845 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19
Phase 3 Adolescent Study for SARS-CoV-2 rS Variant Vaccines
This study is a large-scale investigation (Phase 3) into a new booster shot designed specifically for teenagers. The booster targets a particular variant of COVID-19, Omicron XBB.1.5.
- Trial name
- COVID-19 (NCT05973006)
- Testing
- NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine, Prototype/XBB.1.5 Bivalent Vaccine (5 µg)
- Where
- 20 sites in United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Novavax
SARS-CoV-2
A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021)
This trial is a phase I clinical trial of a SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021). The trial used a randomized, blinded, placebo-controlled design to evaluate the safety, tolerability, and preliminary immunogenicity of the…
- Trial name
- NCT05939596
- Testing
- SARS-CoV-2 Bivalent mRNA Vaccine, Saline
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- AIM Vaccine Co., Ltd.
Influenza
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVSQIV in Healthy Adults
This study aims to evaluate the safety and reactogenicity profile of CVSQIV at different dose levels.
- Trial name
- NCT05252338
- Testing
- CVSQIV
- Where
- 3 sites in Panama
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- CureVac
SARS-CoV2 Infection, Coronavirus Infection
Fourth Dose of mRNA COVID-19 Vaccine in Residents of LTCFs
This study is a multi-centre, blinded, randomized controlled trial. LTCF residents ≥ 65 years who have received three doses of mRNA vaccine will be randomized to vaccination with a fourth dose of Pfizer-BioNtech mRNA- COVID-19…
- Trial name
- NCT04978038
- Testing
- mRNA- COVID-19, Prevnar13
- Where
- Canada
- Volunteers
- 414 people, healthy volunteers welcome
- Sponsor
- Mark Loeb
Covid19
COVID-19 Vaccination of Immunodeficient Persons (COVAXID)
The study is designed as an open, non-randomized, phase IV cohort study in which the mRNA vaccine Comirnaty will be given in two doses.
- Trial name
- COVAXID (NCT04780659)
- Testing
- Comirnaty (COVID-19, mRNA vaccine)
- Where
- Sweden
- Volunteers
- 539 people, healthy volunteers welcome
- Sponsor
- Karolinska University Hospital
Hiv
A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core)
A Phase 1, Randomized, First-in-human, Open-label Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core) in HIV-1 Uninfected Adults in Good…
- Trial name
- NCT05001373
- Testing
- Core-g28v2 60mer mRNA Vaccine, eOD-GT8 60mer mRNA Vaccine
- Where
- 4 sites in United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- International AIDS Vaccine Initiative
COVID-19
COVID-19 Booster Study in Healthy Adults in Australia
This is a double-blinded, randomised study to determine the safety, reactogenicity, and immunogenicity of a bivalent mRNA Moderna COVID-19 vaccine or a protein-based Novavax COVID-19 vaccine given as a fourth dose in healthy…
- Trial name
- NCT05658523
- Testing
- Bivalent Moderna, Novavax
- Where
- Australia
- Volunteers
- 496 people, healthy volunteers welcome
- Sponsor
- Murdoch Childrens Research Institute
SARS-CoV-2
Safety and Immune Response of Adjuvanted SARS-CoV-2 (COVID-19) Beta Variant RBD Recombinant Protein (DoCo-Pro-RBD-1 + MF59®) and mRNA (MIPSCo-mRNA-RBD-1) Vaccines in Healthy Adults
This is a study of two experimental SARS-CoV-2 vaccines against the virus called SARS-CoV-2 virus. The first of the experimental vaccines is called DoCo-Pro-RBD-1 + M59® and contains a laboratory made protein which looks the same…
- Trial name
- NCT05272605
- Testing
- Adjuvanted SARS-CoV-2 beta variant RBD recombinant protein vaccine (DoCo-Pro-RBD-1 + MF59), SARS-CoV-2 beta variant RBD mRNA vaccine, Normal Saline
- Where
- 2 sites in Australia
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- University of Melbourne
Respiratory Syncytial Virus Infections
A Study on the Safety and Immune Response to an mRNA-based RSV Investigational Vaccine in Healthy Adults Aged 18-45 Years
The purpose of this study is to assess the reactogenicity, safety and immune response of various formulations of the RSV mRNA investigational vaccine administered in healthy participants 18-45 years of age.
- Trial name
- NCT06573281
- Testing
- Investigational RSV vaccine 1, Investigational RSV vaccine 2, Investigational RSV vaccine 3
- Where
- 9 sites in United States, Australia and 1 more
- Volunteers
- 213 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
SARS-CoV-2
Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population
This was a phase II, randomized, placebo-controlled, observer-blinded study of the safety and immunogenicity of SARS-CoV-2 messenger RNA (mRNA) vaccine (BNT162b2) in Chinese healthy population.
- Trial name
- NCT04649021
- Testing
- BNT162b2
- Where
- China
- Volunteers
- 960 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Influenza, Human
Safety, Reactogenicity, and Immunogenicity Study of a Self-Amplifying MRNA Influenza Vaccine in Healthy Adults
This is a Phase 1, first-in-human, randomized, placebo-controlled, observer blind study. The effect of two doses of an investigational vaccine on safety, reactogenicity, kinetics and magnitude of the post-vaccination antibody…
- Trial name
- NCT06028347
- Testing
- sa-mRNA vaccine Dose 1, sa-mRNA vaccine Dose 2, sa-mRNA vaccine Dose 3
- Where
- 2 sites in Australia
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Seqirus
Covid19
Factors Influencing the COVID-19 Vaccine Immune Response According to Age and Presence or Not of a Past History of COVID-19
Age is the main risk factor associated with the severity of COVID-19. From the beginning of the vaccination campaign, elderly subjects are part of the priority population.
- Trial name
- COVIMMUNAGE (NCT05047718)
- Testing
- COVID-19 vaccine Pfizer (3 doses), COVID-19 vaccine Pfizer (2 doses), COVID-19 mRNA Vaccine Moderna (3 doses)
- Where
- 2 sites in France
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne